NASDAQ:NSTG - NanoString Technologies Stock Price, Forecast & News

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies Inc (NASDAQ:NSTG) released its earnings results on Monday, November, 4th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.10. The biotechnology company earned $30.60 million during the quarter, compared to analysts' expectations of $28.05 million. NanoString Technologies had a negative return on equity of 118.32% and a negative net margin of 72.30%. View NanoString Technologies' Earnings History.

NanoString Technologies is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for NanoString Technologies.

NanoString Technologies updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125.7-125.7 million, compared to the consensus revenue estimate of $121.36 million.

2 brokerages have issued 12-month price objectives for NanoString Technologies' shares. Their forecasts range from $28.00 to $35.00. On average, they anticipate NanoString Technologies' share price to reach $31.50 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price. View Analyst Price Targets for NanoString Technologies.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.

Media headlines about NSTG stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. NanoString Technologies earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for NanoString Technologies.

Some companies that are related to NanoString Technologies include Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX) and Editas Medicine (EDIT).

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Designer Brands (DBI), Bank Of The Ozarks (OZRK) and Eaton Vance Floating-Rate Income Trust (EFT).

NanoString Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.39%). Company insiders that own NanoString Technologies stock include Charles P Waite, Jr, David W Ghesquiere, J Chad Brown, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.

NSTG stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold NanoString Technologies company stock in the last year include Charles P Waite, Jr, David W Ghesquiere, J Chad Brown, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, R Bradley Gray and William Young. View Insider Buying and Selling for NanoString Technologies.

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NSTG stock can currently be purchased for approximately $29.90.

NanoString Technologies has a market capitalization of $1.07 billion and generates $106.73 million in revenue each year. The biotechnology company earns $-77,400,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. NanoString Technologies employs 476 workers across the globe.View Additional Information About NanoString Technologies.

The official website for NanoString Technologies is http://www.nanostring.com/.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]